You may find more results for this query on our sister sites: GenomeWeb and 360Dx.
The application for Tecentriq as a first-line monotherapy for NSCLC patients without EGFR or ALK mutations and high PD-L1 expression was also granted priority review.
The high-throughput S2000 sequencer is the second instrument Genetron Health has received NMPA approval for, following the S5 benchtop instrument last year.
Capmatinib is being studied as a therapy for untreated and previously treated MET exon 14 skipping mutated non-small cell lung cancer patients.
The trial will assess vopratelimab and Jounce's PD-1 inhibitor in NSCLC patients, and evaluate the ability of an RNA signature to predict response.
Extending a prior agreement with the drugmaker, Personalis will use its DNA/RNA platform to identify both predictive biomarkers and resistance mechanisms.
Oncoprex will be tested in combination of Tagrisso in patients with EGFR-mutated non-small cell lung cancer.
A new analysis has provided evidence that adjuvant lung cancer immunotherapy benefits those with lingering ctDNA, but not necessary those without.
Based on cost-effectiveness estimates and a lack of comparison against afatinib, NICE will recommend against using osimertinib for first-line treatment of NSCLC.
BBT-176, a novel agent designed to inhibit EGFR with C797S mutations, will start first-in-human studies in NSCLC this year.
Five Prime Therapeutics provided an update on the development of bemarituzumab and FPA150, and Gritstone Oncology discussed plans for its personalized immunotherapies.